{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:18:16Z","timestamp":1790486296739,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Duesseldorf School of Oncology, HHU Duesseldorf \/ CCC- Deutsche Krebshilfe"},{"name":"Strategischer Forschungsf\u00f6rderungs Fond, HHU Duesseldorf"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13046-015-0259-x","type":"journal-article","created":{"date-parts":[[2015,11,25]],"date-time":"2015-11-25T13:41:07Z","timestamp":1448458867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Phenotype plasticity rather than repopulation from CD90\/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines"],"prefix":"10.1186","volume":"34","author":[{"given":"Margaretha A.","family":"Skowron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Niegisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Fritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Arent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep G. H.","family":"van Roermund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Albers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le J.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,25]]},"reference":[{"key":"259_CR1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359\u2013E86.","journal-title":"Int J Cancer"},{"key":"259_CR2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/carcin\/bgi310","volume":"27","author":"MA Knowles","year":"2006","unstructured":"Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis. 2006;27:361\u201373.","journal-title":"Carcinogenesis"},{"key":"259_CR3","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.eururo.2011.03.023","volume":"59","author":"A Stenzl","year":"2011","unstructured":"Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011;59:1009\u201318.","journal-title":"Eur Urol"},{"key":"259_CR4","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/1097-0142(20011215)92:12<2993::AID-CNCR10108>3.0.CO;2-2","volume":"92","author":"CN Sternberg","year":"2001","unstructured":"Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer. 2001;92:2993\u20138.","journal-title":"Cancer"},{"key":"259_CR5","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jjco\/hyt096","volume":"43","author":"S Taguchi","year":"2013","unstructured":"Taguchi S, Nakagawa T, Hattori M, Niimi A, Nagata M, Kawai T, et al. Prognostic factors for metastatic urothelial carcinoma undergoing cisplatin-based salvage chemotherapy. Jpn J Clin Oncol. 2013;43:923\u20138.","journal-title":"Jpn J Clin Oncol"},{"key":"259_CR6","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H Maase von der","year":"2005","unstructured":"von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602\u20138.","journal-title":"J Clin Oncol"},{"key":"259_CR7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1586\/era.11.201","volume":"12","author":"RM Drayton","year":"2012","unstructured":"Drayton RM, Catto JWF. Molecular mechanisms of cisplatin resistance in bladder cancer. Expert Rev Anticancer Ther. 2012;12:271\u201381.","journal-title":"Expert Rev Anticancer Ther"},{"key":"259_CR8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nature14034","volume":"517","author":"AV Kurtova","year":"2015","unstructured":"Kurtova AV, Xiao J, Mo QX, Pazhanisamy S, Krasnow R, Lerner SP, et al. Blocking PGE(2)-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2015;517:209\u201324.","journal-title":"Nature"},{"key":"259_CR9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nature14075","volume":"517","author":"IF Tannock","year":"2015","unstructured":"Tannock IF. Cancer: resistance through repopulation. Nature. 2015;517:152\u20133.","journal-title":"Nature"},{"key":"259_CR10","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1073\/pnas.1120605109","volume":"109","author":"JP Volkmer","year":"2012","unstructured":"Volkmer JP, Sahoo D, Chin RK, Ho PL, Tang C, Kurtova AV, et al. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci U S A. 2012;109:2078\u201383.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"259_CR11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.devcel.2013.07.017","volume":"26","author":"D Gandhi","year":"2013","unstructured":"Gandhi D, Molotkov A, Batourina E, Schneider K, Dan HB, Reiley M, et al. Retinoid signaling in progenitors controls specification and regeneration of the urothelium. Dev Cell. 2013;26:469\u201382.","journal-title":"Dev Cell"},{"key":"259_CR12","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/4351169a","volume":"435","author":"BJP Huntly","year":"2005","unstructured":"Huntly BJP, Gilliland DG. Cancer biology: summing up cancer stem cells. Nature. 2005;435:1169\u201370.","journal-title":"Nature"},{"key":"259_CR13","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/ijc.26475","volume":"131","author":"M Tatokoro","year":"2012","unstructured":"Tatokoro M, Koga F, Yoshida S, Kawakami S, Fujii Y, Neckers L, et al. Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells. Int J Cancer. 2012;131:987\u201396.","journal-title":"Int J Cancer"},{"key":"259_CR14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1083\/jcb.201202014","volume":"198","author":"I Baccelli","year":"2012","unstructured":"Baccelli I, Trumpp A. The evolving concept of cancer and metastasis stem cells. J Cell Biol. 2012;198:281\u201393.","journal-title":"J Cell Biol"},{"key":"259_CR15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.urolonc.2009.04.019","volume":"28","author":"M Castillo-Martin","year":"2010","unstructured":"Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C. Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol. 2010;28:401\u20138.","journal-title":"Urol Oncol"},{"key":"259_CR16","doi-asserted-by":"crossref","first-page":"8105","DOI":"10.1073\/pnas.1221216110","volume":"110","author":"JC Pignon","year":"2013","unstructured":"Pignon JC, Grisanzio C, Geng Y, Song JX, Shivdasani RA, Signoretti S. p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. Proc Natl Acad Sci U S A. 2013;110:8105\u201310.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"259_CR17","first-page":"657","volume":"14","author":"J Southgate","year":"1999","unstructured":"Southgate J, Harnden P, Trejdosiewicz LK. Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications. Histol Histopathol. 1999;14:657\u201364.","journal-title":"Histol Histopathol"},{"key":"259_CR18","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/ncb2956","volume":"16","author":"K Shin","year":"2014","unstructured":"Shin K, Lim A, Odegaard JI, Honeycutt JD, Kawano S, Hsieh MH, et al. Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma. Nat Cell Biol. 2014;16:469\u201378.","journal-title":"Nat Cell Biol"},{"key":"259_CR19","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/ncb3038","volume":"16","author":"J Batavia Van","year":"2014","unstructured":"Van Batavia J, Yamany T, Molotkov A, Dan HB, Mansukhani M, Batourina E, et al. Bladder cancers arise from distinct urothelial sub-populations. Nat Cell Biol. 2014;16:982\u201391.","journal-title":"Nat Cell Biol"},{"key":"259_CR20","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:152\u201365.","journal-title":"Cancer Cell"},{"key":"259_CR21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ccr.2014.01.026","volume":"25","author":"CD Hurst","year":"2014","unstructured":"Hurst CD, Knowles MA. Molecular subtyping of invasive bladder cancer: time to divide and rule? Cancer Cell. 2014;25:135\u20136.","journal-title":"Cancer Cell"},{"key":"259_CR22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"The Cancer Genome Atlas Network","year":"2014","unstructured":"The Cancer Genome Atlas Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315\u201322.","journal-title":"Nature"},{"key":"259_CR23","first-page":"3630","volume":"46","author":"JRW Masters","year":"1986","unstructured":"Masters JRW, Hepburn PJ, Walker L, Highman WJ, Trejdosiewicz LK, Povey S, et al. Tissue-culture model of transitional cell-carcinoma: characterization of 22 human urothelial cell-lines. Cancer Res. 1986;46:3630\u20136.","journal-title":"Cancer Res"},{"key":"259_CR24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.tranon.2015.04.002","volume":"8","author":"S Vallo","year":"2015","unstructured":"Vallo S, Michaelis M, Rothweiler F, Bartsch G, Gust KM, Limbart DM, et al. Drug-resistant urothelial cancer cell lines display diverse sensitivity profiles to potential second-line therapeutics. Transl Oncol. 2015;8:210\u20136.","journal-title":"Transl Oncol"},{"key":"259_CR25","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.bjc.6601031","volume":"88","author":"I Thievessen","year":"2003","unstructured":"Thievessen I, Seifert HH, Swiatkowski S, Florl AR, Schulz WA. E-cadherin involved in inactivation of WNT\/beta-catenin signalling in urothelial carcinoma and normal urothelial cells. Brit J Cancer. 2003;88:1932\u20138.","journal-title":"Brit J Cancer"},{"key":"259_CR26","doi-asserted-by":"crossref","first-page":"e45462","DOI":"10.1371\/journal.pone.0045462","volume":"7","author":"P Kaler","year":"2012","unstructured":"Kaler P, Augenlicht L, Klampfer L. Activating mutations in beta-catenin in colon cancer cells alter their interaction with macrophages; the role of snail. Plos One. 2012;7:e45462.","journal-title":"Plos One"},{"key":"259_CR27","doi-asserted-by":"crossref","first-page":"e54193","DOI":"10.1371\/journal.pone.0054193","volume":"8","author":"MP Barr","year":"2013","unstructured":"Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O\u2019Flaherty JD, et al. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. Plos One. 2013;8:e54193.","journal-title":"Plos One"},{"key":"259_CR28","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ijc.28478","volume":"134","author":"DP Freitas","year":"2014","unstructured":"Freitas DP, Teixeira CA, Santos-Silva F, Vasconcelos MH, Almeida GM. Therapy-induced enrichment of putative lung cancer stem-like cells. Int J Cancer. 2014;134:1270\u20138.","journal-title":"Int J Cancer"},{"key":"259_CR29","doi-asserted-by":"crossref","unstructured":"Hatina J, Fernandes MI, Hoffmann MJ, Zeimet AG. Cancer stem cells \u2013 basic biological properties and experimental approaches. 2013. In: eLS. John Wiley & Sons Ltd, Chichester. http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/9780470015902.a0021164.pub2\/abstract;jsessionid=A9BE323B3B459C6FE0397ED1F82ACC61.f04t03 [doi: 10.1002\/9780470015902.a0021164.pub2 ]","DOI":"10.1002\/9780470015902.a0021164.pub2"},{"key":"259_CR30","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrc2499","volume":"8","author":"JE Visvader","year":"2008","unstructured":"Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755\u201368.","journal-title":"Nat Rev Cancer"},{"key":"259_CR31","doi-asserted-by":"crossref","first-page":"13427","DOI":"10.1073\/pnas.0805706105","volume":"105","author":"L Vermeulen","year":"2008","unstructured":"Vermeulen L, Todaro M, Mello FD, Sprick MR, Kemper K, Alea MP, et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A. 2008;105:13427\u201332.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"259_CR32","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/stem.1625","volume":"32","author":"GM Dancik","year":"2014","unstructured":"Dancik GM, Owens CR, Iczkowski KA, Theodorescu D. A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors. Stem Cells. 2014;32:974\u201382.","journal-title":"Stem Cells"},{"key":"259_CR33","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canlet.2014.11.040","volume":"357","author":"A Wang","year":"2015","unstructured":"Wang A, Chen L, Li C, Zhu Y. Heterogeneity in cancer stem cells. Cancer Lett. 2015;357:63\u20138.","journal-title":"Cancer Lett"},{"key":"259_CR34","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.urolonc.2014.01.001","volume":"32","author":"T Hofner","year":"2014","unstructured":"Hofner T, Macher-Goeppinger S, Klein C, Schillert A, Eisen C, Wagner S, et al. Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy. Urol Oncol. 2014;32:678\u201386.","journal-title":"Urol Oncol"},{"key":"259_CR35","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nrc822","volume":"2","author":"JP Thiery","year":"2002","unstructured":"Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442\u201354.","journal-title":"Nat Rev Cancer"},{"key":"259_CR36","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1158\/1078-0432.CCR-14-1215","volume":"21","author":"J Kim","year":"2015","unstructured":"Kim J, Akbani R, Creighton CJ, Lerner SP, Weinstein JN, Getz G, et al. Invasive bladder cancer: genomic insights and therapeutic promise. Clin Cancer Res. 2015;21:4514\u201324.","journal-title":"Clin Cancer Res"},{"key":"259_CR37","doi-asserted-by":"crossref","first-page":"14016","DOI":"10.1073\/pnas.0906549106","volume":"106","author":"KS Chan","year":"2009","unstructured":"Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A. 2009;106:14016\u201321.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"259_CR38","first-page":"733","volume":"32","author":"MJS Falso","year":"2012","unstructured":"Falso MJS, Buchholz BA, White RWD. Stem-like cells in bladder cancer cell lines with differential sensitivity to cisplatin. Anticancer Res. 2012;32:733\u20138.","journal-title":"Anticancer Res"},{"key":"259_CR39","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ajpath.2012.08.011","volume":"181","author":"M Puhr","year":"2012","unstructured":"Puhr M, Hoefer J, Schafer G, Erb HHH, Oh SJ, Klocker H, et al. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol. 2012;181:2188\u2013201.","journal-title":"Am J Pathol"},{"key":"259_CR40","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/cgt.2014.42","volume":"21","author":"S Warrier","year":"2014","unstructured":"Warrier S, Bhuvanalakshmi G, Arfuso F, Rajan G, Millward M, Dharmarajan A. Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition. Cancer Gene Ther. 2014;21:381\u20138.","journal-title":"Cancer Gene Ther"},{"key":"259_CR41","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ejphar.2013.12.004","volume":"723","author":"H Wang","year":"2014","unstructured":"Wang H, Zhang G, Zhang H, Zhang F, Zhou BH, Ning F, et al. Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT\/beta-catenin\/Snail signaling pathway. Eur J Pharmacol. 2014;723:156\u201366.","journal-title":"Eur J Pharmacol"},{"key":"259_CR42","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/onc.2014.136","volume":"34","author":"QH Miow","year":"2015","unstructured":"Miow QH, Tan TZ, Ye J, Lau JA, Yokomizo T, Thiery JP, et al. Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene. 2015;34:1899\u2013907.","journal-title":"Oncogene"},{"key":"259_CR43","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1373\/clinchem.2012.184655","volume":"59","author":"ND Marjanovic","year":"2013","unstructured":"Marjanovic ND, Weinberg RA, Chaffer CL. Cell plasticity and heterogeneity in cancer. Clin Chem. 2013;59:168\u201379.","journal-title":"Clin Chem"},{"key":"259_CR44","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0140-6736(13)62226-6","volume":"383","author":"D Hanahan","year":"2014","unstructured":"Hanahan D. Rethinking the war on cancer. Lancet. 2014;383:558\u201363.","journal-title":"Lancet"},{"key":"259_CR45","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13046-014-0062-0","volume":"33","author":"S Kaufhold","year":"2014","unstructured":"Kaufhold S, Bonavida B. Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. J Exp Clin Cancer Res. 2014;33:62.","journal-title":"J Exp Clin Cancer Res"},{"key":"259_CR46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.canlet.2013.05.005","volume":"336","author":"Y Gao","year":"2013","unstructured":"Gao Y, Liu Z, Zhang XW, He JN, Pan YQ, Hao FX, et al. Inhibition of cytoplasmic GSK-3 beta increases cisplatin resistance through activation of Wnt\/beta-catenin signaling in A549\/DDP cells. Cancer Lett. 2013;336:231\u20139.","journal-title":"Cancer Lett"},{"key":"259_CR47","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/35077219","volume":"411","author":"J Taipale","year":"2001","unstructured":"Taipale J, Beachy PA. The Hedgehog and Wnt signaling pathways in cancer. Nature. 2001;411:349\u201354.","journal-title":"Nature"},{"key":"259_CR48","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nature03319","volume":"434","author":"T Reya","year":"2005","unstructured":"Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843\u201350.","journal-title":"Nature"},{"key":"259_CR49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc1590","volume":"5","author":"M Dean","year":"2005","unstructured":"Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275\u201384.","journal-title":"Nat Rev Cancer"},{"key":"259_CR50","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature09851","volume":"472","author":"K Shin","year":"2011","unstructured":"Shin K, Lee J, Guo N, Kim J, Lim A, Qu LS, et al. Hedgehog\/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature. 2011;472:110\u20134.","journal-title":"Nature"},{"key":"259_CR51","first-page":"1033","volume":"26","author":"MV Cronauer","year":"2005","unstructured":"Cronauer MV, Schulz WA, Ackermann R, Burchardt M. Effects of WNT\/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. Int J Oncol. 2005;26:1033\u201340.","journal-title":"Int J Oncol"},{"key":"259_CR52","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ygyno.2014.04.005","volume":"134","author":"RC Arend","year":"2014","unstructured":"Arend RC, Londono-Joshi AI, Samant RS, Li YH, Conner M, Hidalgo B, et al. Inhibition of Wnt\/beta-catenin pathway by niclosamide: a therapeutic target for ovarian cancer. Gynecol Oncol. 2014;134:112\u201320.","journal-title":"Gynecol Oncol"},{"key":"259_CR53","doi-asserted-by":"crossref","first-page":"djt356","DOI":"10.1093\/jnci\/djt356","volume":"106","author":"DJ Stewart","year":"2014","unstructured":"Stewart DJ. Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst. 2014;106:djt356.","journal-title":"J Natl Cancer Inst"},{"key":"259_CR54","doi-asserted-by":"crossref","first-page":"695603","DOI":"10.1155\/2012\/695603","volume":"2012","author":"J Roma","year":"2012","unstructured":"Roma J, Almazan-Moga A, Sanchez de Toledo J, Gallego S. Notch, wnt, and hedgehog pathways in rhabdomyosarcoma: from single pathways to an integrated network. Sarcoma. 2012;2012:695603.","journal-title":"Sarcoma"},{"key":"259_CR55","doi-asserted-by":"crossref","first-page":"17","DOI":"10.12703\/P5-17","volume":"5","author":"L Attisano","year":"2013","unstructured":"Attisano L, Wrana JL. Signal integration in TGF-beta, WNT, and Hippo pathways. F1000Prime Rep. 2013;5:17.","journal-title":"F1000Prime Rep"},{"key":"259_CR56","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869\u201383.","journal-title":"Oncogene"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-015-0259-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T00:23:19Z","timestamp":1498263799000},"score":1,"resource":{"primary":{"URL":"http:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-015-0259-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,25]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["259"],"URL":"https:\/\/doi.org\/10.1186\/s13046-015-0259-x","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,25]]},"article-number":"144"}}